SCHEMBL481186

SCHEMBL481186

CC(=O)c1ccc(OCc2nc(Cc3cccc(I)c3)no2)c(Cl)c1O

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
TSHR P16473 3/20 0.43
GRM2 Q14416 2/20 0.41
CYSLTR1 Q9Y271 2/20 0.41
GSTP1 P09211 8/20 0.40
TDP1 Q9NUW8 3/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SLC26A3 P40879 1/20 0.39
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 2/20 0.36
FFAR1 O14842 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL481352 0.90 TDP1 (0.52) MAPTTSHRGRM2CYSLTR1GSTP1
SCHEMBL481437 0.89 MAPT (0.48) MAPTTSHRGRM2CYSLTR1GSTP1
SCHEMBL481097 0.88 MRGPRX4 (0.46) MAPTTSHRGRM2CYSLTR1GSTP1
SCHEMBL27795886 0.85 TSHR (0.41) MAPTTSHRGSTP1TDP1L3MBTL1
SCHEMBL480977 0.82 MAPT (0.48) MAPTTSHRGRM2CYSLTR1GSTP1
SCHEMBL481409 0.82 MAPT (0.53) MAPTGRM2CYSLTR1TDP1CYP2C9
SCHEMBL481419 0.81 MRGPRX4 (0.46) MAPTGRM2CYSLTR1TDP1CYP2C9
SCHEMBL481542 0.78 GRM2 (0.40) MAPTGRM2CYSLTR1GSTP1TDP1
SCHEMBL481083 0.78 MAPT (0.50) MAPTTSHRGRM2CYSLTR1GSTP1
SCHEMBL481378 0.78 TDP1 (0.53) MAPTTSHRGRM2CYSLTR1GSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441762-A1 Potentiators of Glutamate Receptors Eli Lilly and Company (US) 2012-04-18 EP disclosed
EP-1817301-B1 POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2012-02-01 EP disclosed
US-7816523-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-10-19 US disclosed
US-7803938-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2010-09-28 US disclosed
US-20090318481-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-20090318483-A1 Potentiators Of Glutamate Receptors AICHER THOMAS DANIEL 2009-12-24 US disclosed
US-7598423-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-10-06 US disclosed
US-20080139505-A1 Potentiators Of Glutamate Receptors ARRAY BIOPHARMA, INC. 2008-06-12 US disclosed
EP-1817301-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-15 EP disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139505-A1 Potentiators Of Glutamate Receptors GRM1, GRIN1, GRM2 MAPT 3525/4885TSHR 248/4885GRM2 3/4885
US-20090318481-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 MAPT 2945/4885TSHR 480/4885GRM2 8/4885
US-20090318483-A1 Potentiators Of Glutamate Receptors GRIK1, GRIK2, GRIK4 MAPT 2945/4885TSHR 480/4885GRM2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.